Evidence map›Paper›PMID 32517802›Full record

ArticleBMC cancer2020

Albumin-to-alkaline phosphatase ratio serves as a prognostic indicator in unresectable pancreatic ductal adenocarcinoma: a propensity score matching analysis.

Ke Zhang, Shu Dong, Yan-Hua Jing, Hui-Feng Gao, Lian-Yu Chen, Yong-Qiang Hua, Hao Chen, Zhen Chen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Ke ZhangDepartment of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Shu DongDepartment of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Yan-Hua JingDepartment of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Hui-Feng GaoDepartment of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Lian-Yu ChenDepartment of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Yong-Qiang HuaDepartment of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Hao ChenDepartment of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. chengkll@sina.com.
Zhen ChenDepartment of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. zchenzl@fudan.edu.cn.ORCID http://orcid.org/0000-0002-4502-0801
Shanghai Medical College of Fudan University · CN

Funding

National Nature Science Foundation of China 81930115National Nature Science Foundation of China 81973616
6 · The paper itself

Abstract

backgroundRecent evidence suggests that albumin-to-Alkaline Phosphatase Ratio (AAPR) functions as a novel prognostic marker in several malignancies. However, whether it can predict the prognosis of unresectable pancreatic ductal adenocarcinoma (PDAC) remains unclear. Herein, we seek to investigate this possibility by a propensity score matching (PSM) analysis.

methodsThis was a retrospective cohort study in which 419 patients diagnosed with unresectable PDAC and receiving chemotherapy were recruited. Patients were stratified based on the cutoff value of AAPR. The PSM analysis was performed to identify 156 well-balanced patients in each group for overall survival (OS) comparison and subgroup analysis. Univariate and multivariate analyses were carried out to examine the potential of AAPR to indicate the prognosis of unresectable PDAC. The prediction performance of conventional model and combined model including AAPR was compared using the Akaike Information Criterion (AIC) and concordance index (C-index).

resultsWe identified an AAPR of 0.4 to be the optimal cutoff for OS prediction. Patients with AAPR≤0.4 had significantly shorter OS compared with patients with AAPR> 0.4 (6.4 versus 9.3 months; P < 0.001). Based on the PSM cohort and entire cohort, multivariate Cox analysis revealed that high pretreatment for AAPR was an independent marker predicting favorable survival in unresectable PDAC (hazard ratio, 0.556; 95% confidence interval, 0.408 to 0.757; P < 0.001). Significant differences in OS were observed in all subgroups except for the group of patients age ≤ 60. Combined prognostic model including AAPR had lower AIC and higher C-index than conventional prognostic model.

conclusionsPretreatment AAPR servers as an independent prognostic indicator for patients with unresectable PDAC. Inclusion of AAPR improved the prediction performance of conventional prognostic model, potentially helping clinicians to identify patients at high risk and guide individualized treatment.

Indexed as

AdultAgedAged, 80 and overAge FactorsAlkaline PhosphataseAnalysis of VarianceBiomarkers, TumorCarcinoma, Pancreatic DuctalChi-Square DistributionConfidence IntervalsFemaleHumansMaleMiddle AgedPancreatic NeoplasmsPrognosisAlkaline PhosphataseBiomarkers, TumorSerum AlbuminAlbumin-to-alkaline phosphatase ratioOverall survivalPancreatic ductal adenocarcinomaPrognostic markerPropensity score matching

Identifiers

PMID32517802
PMCPMC7285790
OpenAlexW3033919932

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.